Loading
companiesCompany
Prelude Therapeutics
Prelude Therapeutics develops precision cancer medicines. Its current focus is a pill for blood cancers driven by a JAK2 mutation and drugs that destroy a protein called KAT6A in hormone-driven breast cancer.
Overview
Prelude Therapeutics is a Wilmington, Delaware clinical-stage precision oncology company. Its pipeline page lists PR-01, a JAK2 V617F mutant-selective JH2 inhibitor in a phase 1 trial enrolling patients with V617F-positive myeloproliferative neoplasms (myelofibrosis, polycythaemia vera, essential thrombocythaemia); highly selective KAT6A degraders for ER-positive breast cancer, with phase 1 initiation anticipated in the fourth quarter of 2026; a mutant CALR-directed degrader antibody conjugate (DAC) for CALR-mutated MPNs; and degrader payloads for DACs offered for partnership. Earlier PRMT5 (PRT543, PRT811) and MCL1 programmes have been deprioritised. Prelude completed its Nasdaq IPO in September 2020, raising about 181.9 million US dollars gross.
Headquarters
Wilmington, DE, US
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · Gross proceeds of about 181.9 million US dollars, September 2020 | 2020 | $182M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · PRLD
Stage
Public
Website
Notes
top- Myeloproliferative neoplasms have no id in the cancer list. Founding year not sourced. The statement that earlier PRMT5 and MCL1 programmes were deprioritised is inferred from their absence on the current pipeline page.
Similar pages
- CompanyCullgen
Shares Degrader-antibody conjugate (DAC), PROTACs & molecular glues (targeted protein degradation).
- TechnologyKAT6 inhibitors
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), HR-positive / HER2-negative breast cancer.
- CompanyPlexium
Shares PROTACs & molecular glues (targeted protein degradation), HR-positive / HER2-negative breast cancer.
- CompanyProxygen
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- CompanyOrum Therapeutics
Shares Degrader-antibody conjugate (DAC), PROTACs & molecular glues (targeted protein degradation).
- CompanyTreeline Biosciences
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- CompanyBoundless Bio
Shares PROTACs & molecular glues (targeted protein degradation), HR-positive / HER2-negative breast cancer.
- CompanyFoghorn Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation), HR-positive / HER2-negative breast cancer.